Side-by-side comparison of AI visibility scores, market position, and capabilities
Charlotte NC largest US steel producer (NYSE: NUE) ~$30B 2024 revenue; EAF mini-mills (lower carbon, flexible), $10B+ capacity expansion since 2018, 200+ consecutive quarters dividend competing with Cleveland-Cliffs and Steel Dynamics.
Nucor Corporation is a Charlotte, North Carolina-based steel and steel products manufacturer — publicly traded on the New York Stock Exchange (NYSE: NUE) as an S&P 500 Materials component — operating as the largest steel producer in the United States and the most profitable steelmaker in North America, using electric arc furnace (EAF) technology to produce flat-rolled steel, long steel products, structural steel, and steel products at approximately 25 steel mills and 40+ downstream fabrication facilities, through approximately 32,000 employees. Nucor's EAF-based steelmaking model (melting recycled steel scrap rather than processing iron ore in a blast furnace) produces a lower-carbon-intensity ton of steel at lower operating cost and with significantly more production flexibility than integrated blast furnace producers — making Nucor the cost benchmark against which competing steel technologies are measured. In 2024, Nucor navigated a steel price correction after the 2021-2022 post-pandemic construction and infrastructure demand surge — revenue declined from approximately $36-37 billion at the 2022 peak to approximately $30 billion in 2024 as flat-rolled steel prices normalized. Nucor has invested more than $10 billion in capacity expansion since 2018 — including new sheet mills in Gallatin, Kentucky; Lexington, North Carolina; Nucor Steel West Virginia; and Nucor Steel Brandenburg — dramatically increasing its flat-rolled sheet production capacity to serve automotive, construction, and advanced manufacturing customers. CEO Leon Topalian has led Nucor's strategy of organic capacity expansion, new product development, and shareholder-friendly capital allocation (dividends paid for 200+ consecutive quarters).
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.